Pharmacotherapy for pediatric soft-tissue sarcomas

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Introduction: Soft-tissue sarcomas are rare, but they represent about 8% of all malignancies in pediatric age. Developing a multidisciplinary approach to treatment based on risk stratification has led to a dramatic improvement in survival, but a plateau has been reached with current treatment options in the last 20 years. Chemotherapy is usually effective for rhabdomyosarcoma and should be seen as the keystone of its treatment, while non-rhabdomyosarcoma soft-tissue sarcomas are still generally considered scarcely chemosensitive. Areas covered: An overview of current, emerging and possible future medical therapies for pediatric soft-tissue sarcomas is provided. Insight into different chemotherapeutic strategies based on risk stratification for rhabdomyosarcoma and non-rhabdomyosarcoma soft tissue sarcomas in pediatric age is given. Expert opinion: Integrating systemic therapy with local treatments (surgery and/or radiotherapy) is complex and requires adequate experience, which can only be assured by referral institutions. Future challenges include identifying novel targeted therapies and optimizing treatment protocols for customized patient care.

Original languageEnglish
Pages (from-to)517-531
Number of pages15
JournalExpert Opinion on Pharmacotherapy
Volume12
Issue number4
DOIs
Publication statusPublished - Mar 2011

Fingerprint

Sarcoma
Pediatrics
Drug Therapy
Rhabdomyosarcoma
Therapeutics
Expert Testimony
Clinical Protocols
Patient Care
Radiotherapy
Referral and Consultation
Neoplasms

Keywords

  • Chemotherapy
  • Children
  • Non-rhabdomyosarcoma soft-tissue sarcoma
  • Rhabdomyosarcoma
  • Soft-tissue sarcoma

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Pharmacotherapy for pediatric soft-tissue sarcomas. / Casanova, Michela; Ferrari, Andrea.

In: Expert Opinion on Pharmacotherapy, Vol. 12, No. 4, 03.2011, p. 517-531.

Research output: Contribution to journalArticle

@article{51cf7bdb78fa470eb6cd0d09617d8f3a,
title = "Pharmacotherapy for pediatric soft-tissue sarcomas",
abstract = "Introduction: Soft-tissue sarcomas are rare, but they represent about 8{\%} of all malignancies in pediatric age. Developing a multidisciplinary approach to treatment based on risk stratification has led to a dramatic improvement in survival, but a plateau has been reached with current treatment options in the last 20 years. Chemotherapy is usually effective for rhabdomyosarcoma and should be seen as the keystone of its treatment, while non-rhabdomyosarcoma soft-tissue sarcomas are still generally considered scarcely chemosensitive. Areas covered: An overview of current, emerging and possible future medical therapies for pediatric soft-tissue sarcomas is provided. Insight into different chemotherapeutic strategies based on risk stratification for rhabdomyosarcoma and non-rhabdomyosarcoma soft tissue sarcomas in pediatric age is given. Expert opinion: Integrating systemic therapy with local treatments (surgery and/or radiotherapy) is complex and requires adequate experience, which can only be assured by referral institutions. Future challenges include identifying novel targeted therapies and optimizing treatment protocols for customized patient care.",
keywords = "Chemotherapy, Children, Non-rhabdomyosarcoma soft-tissue sarcoma, Rhabdomyosarcoma, Soft-tissue sarcoma",
author = "Michela Casanova and Andrea Ferrari",
year = "2011",
month = "3",
doi = "10.1517/14656566.2011.524926",
language = "English",
volume = "12",
pages = "517--531",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "4",

}

TY - JOUR

T1 - Pharmacotherapy for pediatric soft-tissue sarcomas

AU - Casanova, Michela

AU - Ferrari, Andrea

PY - 2011/3

Y1 - 2011/3

N2 - Introduction: Soft-tissue sarcomas are rare, but they represent about 8% of all malignancies in pediatric age. Developing a multidisciplinary approach to treatment based on risk stratification has led to a dramatic improvement in survival, but a plateau has been reached with current treatment options in the last 20 years. Chemotherapy is usually effective for rhabdomyosarcoma and should be seen as the keystone of its treatment, while non-rhabdomyosarcoma soft-tissue sarcomas are still generally considered scarcely chemosensitive. Areas covered: An overview of current, emerging and possible future medical therapies for pediatric soft-tissue sarcomas is provided. Insight into different chemotherapeutic strategies based on risk stratification for rhabdomyosarcoma and non-rhabdomyosarcoma soft tissue sarcomas in pediatric age is given. Expert opinion: Integrating systemic therapy with local treatments (surgery and/or radiotherapy) is complex and requires adequate experience, which can only be assured by referral institutions. Future challenges include identifying novel targeted therapies and optimizing treatment protocols for customized patient care.

AB - Introduction: Soft-tissue sarcomas are rare, but they represent about 8% of all malignancies in pediatric age. Developing a multidisciplinary approach to treatment based on risk stratification has led to a dramatic improvement in survival, but a plateau has been reached with current treatment options in the last 20 years. Chemotherapy is usually effective for rhabdomyosarcoma and should be seen as the keystone of its treatment, while non-rhabdomyosarcoma soft-tissue sarcomas are still generally considered scarcely chemosensitive. Areas covered: An overview of current, emerging and possible future medical therapies for pediatric soft-tissue sarcomas is provided. Insight into different chemotherapeutic strategies based on risk stratification for rhabdomyosarcoma and non-rhabdomyosarcoma soft tissue sarcomas in pediatric age is given. Expert opinion: Integrating systemic therapy with local treatments (surgery and/or radiotherapy) is complex and requires adequate experience, which can only be assured by referral institutions. Future challenges include identifying novel targeted therapies and optimizing treatment protocols for customized patient care.

KW - Chemotherapy

KW - Children

KW - Non-rhabdomyosarcoma soft-tissue sarcoma

KW - Rhabdomyosarcoma

KW - Soft-tissue sarcoma

UR - http://www.scopus.com/inward/record.url?scp=79951646505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951646505&partnerID=8YFLogxK

U2 - 10.1517/14656566.2011.524926

DO - 10.1517/14656566.2011.524926

M3 - Article

C2 - 21306288

AN - SCOPUS:79951646505

VL - 12

SP - 517

EP - 531

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 4

ER -